Disclosed is a type of indolo heptamyl oxime analog crystalline form as a PARP inhibitor and a method for preparing the same, specifically relating to a crystalline form of a compound of formula (I) and a method for preparing the same.

##STR00001##

Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods to recover wild-type function to p53 mutants. The compounds of the present invention can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

The present invention relates to compounds suitable for use in electronic devices, and to electronic devices, especially organic electroluminescent devices, comprising these compounds.

The present invention relates to compounds suitable for use in electronic devices, and to electronic devices, especially organic electroluminescent devices, comprising these compounds.

The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of R.sub.A or R.sub.1 comprises Ar.sub.1, wherein Ar.sub.1 is an antibiotic resistance breaker moiety which comprises an optionally substituted C.sub.6-10 aryl, C.sub.7-13 aralkyl, C.sub.5-10 heteroaryl, C.sub.6-13 heteroaralkyl, C.sub.5-10 heterocyclyl, C.sub.6-13 heterocyclalkyl, C.sub.3-10 carbocyclyl, C.sub.4-13 carbocyclalkyl, —C(═NR′)—NR′R″ or —CH.sub.2—CH═CH.sub.2 group; wherein after administration of the compound to a bacterial infection this moiety reduces or prevents efflux. The invention also discloses pharmaceutical compositions comprising compounds of formula (A1) and the use of such compounds as medicaments, in particular, to treat bacterial infections, such as drug-resistant bacterial infections.

The invention relates to antibiotic compounds of formula (A1) and pharmaceutically acceptable salts, solvates, tautomers and combinations thereof, wherein X and L are optional linkers and one of R.sub.A or R.sub.1 comprises Ar.sub.1, wherein Ar.sub.1 is an antibiotic resistance breaker moiety which comprises an optionally substituted C.sub.6-10 aryl, C.sub.7-13 aralkyl, C.sub.5-10 heteroaryl, C.sub.6-13 heteroaralkyl, C.sub.5-10 heterocyclyl, C.sub.6-13 heterocyclalkyl, C.sub.3-10 carbocyclyl, C.sub.4-13 carbocyclalkyl, —C(═NR′)—NR′R″ or —CH.sub.2—CH═CH.sub.2 group; wherein after administration of the compound to a bacterial infection this moiety reduces or prevents efflux. The invention also discloses pharmaceutical compositions comprising compounds of formula (A1) and the use of such compounds as medicaments, in particular, to treat bacterial infections, such as drug-resistant bacterial infections.

The present specification relates to an organic light emitting device including: an anode; a cathode disposed to face the anode; and a light emitting layer disposed between the anode and the cathode, in which the light emitting layer includes: a host including a P-type host and an N-type host, which produce an exciplex; and a phosphorescent dopant, and the host including the P-type host and the N-type host, which produce an exciplex, emits a photoluminescence light with a longer wavelength than a wavelength of each of the P-type host and the N-type host.

The present specification relates to an organic light emitting device including: an anode; a cathode disposed to face the anode; and a light emitting layer disposed between the anode and the cathode, in which the light emitting layer includes: a host including a P-type host and an N-type host, which produce an exciplex; and a phosphorescent dopant, and the host including the P-type host and the N-type host, which produce an exciplex, emits a photoluminescence light with a longer wavelength than a wavelength of each of the P-type host and the N-type host.

The present invention relates to a composition which comprises an electron-transporting host and a hole-transporting host, to the use thereof in electronic devices and to electronic devices containing this composition. The electron-transporting host is particularly preferably selected from the class of the triazine-dibenzofuran-carbazole systems or the class of the triazine-dibenzothiophene-carbazole systems. The hole-transporting host is preferably selected from the class of the biscarbazoles.

Provided herein are compounds having the following structural formula, wherein values for the variables are as described herein. Also provided are pharmaceutical compositions of the compounds, as well as methods of using the compounds to inhibit the oxidative pentose phosphate pathway, e.g, to treat cancer, malaria, an autoimmune disease, an inflammatory condition or asthma.